FDA Advisory Panel Debates Science On Human Adverse Biological Reactions To Metal-Containing Devices
Executive Summary
US FDA scientists and immunological experts discussed the latest science regarding patients’ biological reactions to metal implants and mercury in dental amalgam at a 13-14 November agency advisory committee meeting. The get-together was held to determine what additional actions the FDA can take to make sure certain patients are protected from immunological risks of the implants. The panel ultimately backed a transition away from mercury amalgam dental fillings and pushed for more research into risks associated with metal implants.
You may also be interested in...
FDA Wants Feedback On How To Properly Label Devices With Risky Materials
The US agency wants stakeholders to chime in on what information should be included in product labels to notify patients about potential side-effects of medical device materials, without being too burdensome for manufacturers.
FDA Guidance: Sponsors Of Nitinol Devices Must Address Thermomechanical Properties Of Alloy
A new FDA final technical guidance on devices containing nitinol spells out special testing considerations and preferred labeling for the medtech products.
CDRH’s Shuren Talks MDUFA, Industry’s Premarket Wants, Emerging Technologies, And More In Wide-Ranging Interview
In an exclusive interview with Medtech Insight, FDA device center director Jeff Shuren said the agency will possibly discuss issues such as postmarket surveillance and patient engagement in upcoming MDUFA negotiations. He also talked about some recent big wins for the agency and his vision for the coming year.